Skip to main content
OpenTrials
Completed

NCT Number: NCT01324362

GSK BHR Study (Sont - Second Study)

The purpose of this study was to determine whether asthma control and reduced bronchial responsiveness could be achieved and maintained at a lower dose of inhaled corticosteroids with ADVAIR DISKUS BID or FP BID in adult and adolescent patients with persistent asthma

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Asthma Bronchial Diseases Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Lung Diseases Lung Diseases, Obstructive Respiratory Hypersensitivity Respiratory Tract Diseases

Age range

12 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

GSK Investigational Site, Rio de Janeiro, Brazil

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of asthma
  • Controller asthma medication or medium dose ICS
  • Current or historical reversibility

Exclusion criteria

  • Life-threatening asthma
  • Asthma instability
  • Concurrent respiratory disease
  • Drug allergies
  • Respiratory tract infection
  • Systemic corticosteroid use
  • Immunosuppressive medication use
  • Postive pregnancy test
  • Tobacco use
  • Investigation medication use
  • Site affiliation

Treatment and study plan

Placebo

Drug

Twice daily dosing

Other names: FP 100mcg, FP 250mcg, FP 500mcg

FP 100mcg

Drug

Twice daily dosing

FP 250mcg

Drug

Twice daily dosing

FP 500mcg

Drug

Twice daily dosing

FSC 100/50mcg

Drug

Twice daily dosing

FSC 250/50mcg

Drug

Twice daily dosing

FSC500/50mcg

Drug

Twice daily dosing

Primary outcomes

  1. Average ICS treatment dose over the treatment period

    Time frame: Every 8 weeks through 40 weeks of treatment

Secondary outcomes

  1. Pulmonary function measures

    Time frame: Every 8 weeks through 40 weeks of treatment

Sponsors and collaborators

Lead sponsor

GlaxoSmithKline

Industry

Registry information

Official study title

A Multicenter, Randomized, Double-blind, Parallel Group, 40-week Comparison of Asthma Control Using Bronchial Hyperresponsiveness as an Additional Guide to Long-term Treatment in Adolescents and Adults Receiving Either Fluticasone Propionate/Sameterol DISKUS Twice Daily or Fluticasone Propionate DISKUS Twice Daily (or Placebo Twice Daily if Asymptomatic)

Important dates

Study start
2003
Primary completion
2004
Study completion
2004
First posted
Mar 29, 2011
Registry last updated
Sep 1, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.